Sight Sciences (NASDAQ:SGHT – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports.
According to Zacks, “Sight Sciences Inc. is a medical device company. It focused on the development and commercialization of proprietary devises which target the underlying causes of prevalent eye diseases. Sight Sciences Inc. is based in MENLO PARK, Calif. “
Several other equities research analysts have also commented on the stock. Morgan Stanley raised shares of Sight Sciences from an “equal weight” rating to an “overweight” rating and cut their price target for the stock from $36.00 to $27.00 in a report on Friday, January 7th. William Blair began coverage on shares of Sight Sciences in a report on Thursday, February 3rd. They issued an “outperform” rating for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Sight Sciences currently has a consensus rating of “Buy” and an average price target of $36.00.
Shares of NASDAQ SGHT opened at $15.28 on Thursday. The firm has a fifty day moving average of $15.94 and a 200 day moving average of $21.53. The company has a debt-to-equity ratio of 0.13, a current ratio of 27.91 and a quick ratio of 27.62. Sight Sciences has a one year low of $13.02 and a one year high of $42.57.
Several institutional investors have recently added to or reduced their stakes in SGHT. Deutsche Bank AG purchased a new stake in shares of Sight Sciences during the third quarter worth $162,000. Advisor Group Holdings Inc. purchased a new stake in shares of Sight Sciences during the third quarter worth $45,000. Jennison Associates LLC purchased a new stake in shares of Sight Sciences during the third quarter worth $879,000. BlackRock Inc. purchased a new stake in shares of Sight Sciences during the third quarter worth $13,547,000. Finally, Alliancebernstein L.P. purchased a new stake in shares of Sight Sciences during the third quarter worth $28,324,000. 49.17% of the stock is owned by institutional investors and hedge funds.
Sight Sciences Company Profile
Sight Sciences Inc is a medical device company. It focused on the development and commercialization of proprietary devises which target the underlying causes of prevalent eye diseases. Sight Sciences Inc is based in MENLO PARK, Calif.